Mga Batayang Estadistika
| LEI | 529900O3044NO0PEA039 |
| CIK | 1070494 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to ACADIA Pharmaceuticals Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 7, 2025 |
Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 1 TO LEASE AND LEASE AGREEMENT AMENDMENT NO. 1 TO LEASE AND LEASE AGREEMENT (this “Amendment”), dated as of May 15, 2025 (the “Effective Date”), between BOSTON PROPER |
|
| August 7, 2025 |
Exhibit 10.4 Acadia Pharmaceuticals Inc. PSU Award Grant Notice (2024 Inducement Plan) Acadia Pharmaceuticals Inc. (the “Company”) has awarded to you (the “Participant”) the number of performance stock units specified and on the terms set forth below (the “PSU Award”). Your PSU Award is subject to all of the terms and conditions as set forth herein and in the Company’s 2024 Inducement Plan (the “P |
|
| August 7, 2025 |
Exhibit 10.5 Acadia Pharmaceuticals Inc. PSU Award Grant Notice (2024 Equity Incentive Plan) Acadia Pharmaceuticals Inc. (the “Company”) has awarded to you (the “Participant”) the number of performance stock units specified and on the terms set forth below in consideration of your services (the “PSU Award”). Your PSU Award is subject to all of the terms and conditions as set forth herein and in th |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-50768 ACADIA PHARMACEUTICALS INC. (Exact Name of Registrant a |
|
| August 7, 2025 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LEASE AND LEASE AGREEMENT Between 210 ASSOCIATES LIMITED PARTNERSHIP The Landlord And ACADIA PHARMACEUTICALS INC. The Tenant For Leased Premises In 210 Carnegie Center Princeton, N |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2025 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 6, 2025 |
Exhibit 99.1 Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview - Second quarter total revenues of $264.6 million, up 9% year-over-year - Second quarter NUPLAZID® (pimavanserin) net product sales of $168.5 million, up 7% year-over-year - Second quarter DAYBUE® (trofinetide) net product sales of $96.1 million, up 14% year-over-year - Raising low end of NUPLA |
|
| June 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2025 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2025 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 21, 2025 |
ACADIA PHARMACEUTICALS INC. 12830 El Camino Real, Suite 400 San Diego, California 92130 CORRESP ACADIA PHARMACEUTICALS INC. 12830 El Camino Real, Suite 400 San Diego, California 92130 May 21, 2025 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street N.E. Washington, D.C. 20549-3010 Attention: Alan Campbell Re: Acadia Pharmaceuticals Inc. Registration Statement on Form S-3 Filed: May 9, 2025 File No. 333-287145 Ladies and Gentlemen: |
|
| May 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 9, 2025 |
Calculation of Registration Fee. Exhibit 107 Calculation of Filing Fee Tables S-3 Acadia Pharmaceuticals Inc. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Ini |
|
| May 9, 2025 |
As filed with the Securities and Exchange Commission on May 9, 2025 Table of Contents As filed with the Securities and Exchange Commission on May 9, 2025 Registration No. |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-50768 ACADIA PHARMACEUTICALS INC. (Exact Name of Registrant |
|
| May 8, 2025 |
Non-Employee Director Compensation Policy, effective April 14, 2025. Acadia Pharmaceuticals Inc. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) of Acadia Pharmaceuticals Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, a “Non-Employee Director”) will, automatically and without further action by the Board or the Compensation Committee of the Board ( |
|
| May 7, 2025 |
Exhibit 99.1 Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview - First quarter total revenues of $244.3 million, up 19% year-over-year - First quarter NUPLAZID® (pimavanserin) net product sales of $159.7 million, up 23% year-over-year - First quarter DAYBUE® (trofinetide) net product sales of $84.6 million, up 11% year-over-year, and up 9.5% in unique patie |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 07, 2025 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 25, 2025 |
ADIA 2023 PROXY STATEMENT SCHEDULE 14A ACADIA 2025 PROXY STATEMENT Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to § 240. |
|
| April 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2025 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| April 16, 2025 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF ACADIA PHARMACEUTICALS INC. (A DELAWARE CORPORATION) AMENDED AND RESTATED BYLAWS OF ACADIA PHARMACEUTICALS INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of Acadia Pharmaceuticals Inc. (the “Corporation”) in the State of Delaware and the name of the Corporation’s registered agent at such address shall b |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50768 ACADIA PHARMAC |
|
| February 27, 2025 |
Asset Purchase Agreement dated November 5, 2024 with respect to sale of a priority review voucher. Exhibit 10.43 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL Execution Version ASSET PURCHASE AGREEMENT BY AND BETWEEN [***] AND ACADIA PHARMACEUTICALS INC. November 5, 2024 TABLE OF CONTENTS RECITALS 1 ARTICLE 1 DEFINITIONS 1 ARTICLE 2 PURC |
|
| February 27, 2025 |
Acadia Pharmaceuticals Inc. Insider Trading Policy. Exhibit 19.1 ACADIA PHARMACEUTICALS INC. Insider Trading Policy (Adopted November 13, 2024) Introduction During the course of your relationship with Acadia Pharmaceuticals Inc. (the “Company,” “we,” “us” or “our”), you may receive material information that is not yet publicly available (“material nonpublic information”) about the Company or other publicly traded companies that the Company has busi |
|
| February 27, 2025 |
List of subsidiaries of the Registrant. Exhibit 21.1 List of Subsidiaries NAME OF SUBSIDIARY JURISDICTION OF INCORPORATION Acadia Pharma Limited England and Wales Acadia Pharmaceuticals A/S Denmark Acadia Pharmaceuticals GmbH Acadia Pharmaceuticals Holdings Inc. Acadia Pharmaceuticals (Canada) Inc. Switzerland Delaware Ontario, Canada Acadia Pharmaceuticals (France) SAS France Acadia Pharmaceuticals (Germany) GmbH Germany Acadia Pharmac |
|
| February 27, 2025 |
Lease Agreement, effective October 4, 2018, by and between the Registrant and Kilroy Realty, L.P. Exhibit 10.31 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. ONE PASEO OFFICE LEASE This Office Lease (this “Lease”), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the “Summary”), below, is made by |
|
| February 27, 2025 |
Exhibit 10.30 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Neuren Pharmaceuticals Limited and ACADIA Pharmaceuticals Inc. Licence Agreement TABLE OF CONTENTS Page no. 1 Definitions and Interpretation1 1.1 Definitions1 1.2 Interpretation |
|
| February 27, 2025 |
Employment Offer Letter, dated November 15, 2024, by and between the Registrant and Thomas Garner. Exhibit 10.16 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. November 15, 2024 Thomas Garner […***…] Dear Tom: We are delighted to offer you the position of EVP, Chief Commercial Officer, which is based in our Princeton, NJ office, with A |
|
| February 26, 2025 |
Exhibit 99.1 Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview - 2024 total net product sales of $957.8 million, reflecting 32% revenue growth - Fourth quarter DAYBUE™ (trofinetide) net product sales of $96.7 million and full year 2024 net product sales of $348.4 million - Fourth quarter NUPLAZID® (pimavanserin) net product sales of $162.9 mi |
|
| February 26, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Comm |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2024 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2024 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 14, 2024 |
SC 13G/A 1 p24-3260sc13ga.htm ACADIA PHARMACEUTICALS INC SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Acadia Pharmaceuticals Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 004225108 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this st |
|
| November 7, 2024 |
Exhibit 10.6 Acadia Pharmaceuticals Inc. PSU Award Grant Notice (2024 Inducement Plan) Acadia Pharmaceuticals Inc. (the “Company”) has awarded to you (the “Participant”) the number of performance stock units specified and on the terms set forth below (the “PSU Award”). Your PSU Award is subject to all of the terms and conditions as set forth herein and in the Company’s 2024 Inducement Plan (the “P |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-50768 ACADIA PHARMACEUTICALS INC. (Exact Name of Registr |
|
| November 6, 2024 |
Exhibit 99.1 Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview - 3Q24 total revenues of $250.4 million, up 18% year-over-year - 3Q24 NUPLAZID® (pimavanserin) net product sales of $159.2 million, up 10% year-over-year - 3Q24 DAYBUE™ (trofinetide) net product sales of $91.2 million, up 36% year-over-year SAN DIEGO, CA, November 6, 2024 – Acadia Pharmaceutical |
|
| November 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 06, 2024 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Comm |
|
| September 23, 2024 |
As filed with the Securities and Exchange Commission on September 23, 2024 As filed with the Securities and Exchange Commission on September 23, 2024 Registration No. |
|
| September 23, 2024 |
EX-10.1 Exhibit 10.1 EXECUTION VERSION ACADIA PHARMACEUTICALS INC. EXECUTIVE TRANSITION AGREEMENT This Executive Transition Agreement (“Transition Agreement”), replaces and supersedes the Amended and Restated Executive Employment Agreement dated September 1, 2015 (the “Employment Agreement”) and all other employment or employment-related agreements or commitments entered into prior to the Effectiv |
|
| September 23, 2024 |
EX-10.2 Exhibit 10.2 EXECUTION VERSION EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is made and entered into effective as of September 23, 2024 (the “Effective Date”) by and between Acadia Pharmaceuticals Inc., a Delaware Corporation (the “Company”), and Catherine Owen Adams (“Executive”). The Company and Executive are hereinafter collectively referred to as the “Part |
|
| September 23, 2024 |
Exhibit 99.2 Standard Form ACADIA PHARMACEUTICALS INC. STOCK OPTION GRANT NOTICE (2024 INDUCEMENT PLAN) Acadia Pharmaceuticals Inc. (the “Company”), pursuant to its 2024 Inducement Plan (the “Plan”), has granted to you (“Optionholder”) an option to purchase the number of shares of the Common Stock set forth below (the “Option”). Your Option is subject to all of the terms and conditions as set fort |
|
| September 23, 2024 |
Exhibit 107 Calculation of Filing Fee Tables S-8 Acadia Pharmaceuticals Inc. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2024 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Com |
|
| September 23, 2024 |
Exhibit 99.1 ACADIA PHARMACEUTICALS INC. 2024 INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: September 20, 2024 1. GENERAL. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under Nasda |
|
| September 23, 2024 |
Exhibit 99.3 Standard Form ACADIA PHARMACEUTICALS INC. RSU AWARD GRANT NOTICE (2024 INDUCEMENT PLAN) Acadia Pharmaceuticals Inc. (the “Company”) has awarded to you (the “Participant”) the number of restricted stock units specified and on the terms set forth below (the “RSU Award”). Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Company’s 2024 Inducement |
|
| August 20, 2024 |
As filed with the Securities and Exchange Commission on August 20, 2024 As filed with the Securities and Exchange Commission on August 20, 2024 Registration No. |
|
| August 20, 2024 |
As filed with the Securities and Exchange Commission on August 20, 2024 As filed with the Securities and Exchange Commission on August 20, 2024 Registration No. |
|
| August 20, 2024 |
As filed with the Securities and Exchange Commission on August 20, 2024 As filed with the Securities and Exchange Commission on August 20, 2024 Registration No. |
|
| August 20, 2024 |
As filed with the Securities and Exchange Commission on August 20, 2024 As filed with the Securities and Exchange Commission on August 20, 2024 Registration No. |
|
| August 20, 2024 |
As filed with the Securities and Exchange Commission on August 20, 2024 As filed with the Securities and Exchange Commission on August 20, 2024 Registration No. |
|
| August 20, 2024 |
As filed with the Securities and Exchange Commission on August 20, 2024 As filed with the Securities and Exchange Commission on August 20, 2024 Registration No. |
|
| August 20, 2024 |
As filed with the Securities and Exchange Commission on August 20, 2024 As filed with the Securities and Exchange Commission on August 20, 2024 Registration No. |
|
| August 20, 2024 |
As filed with the Securities and Exchange Commission on August 20, 2024 As filed with the Securities and Exchange Commission on August 20, 2024 Registration No. |
|
| August 20, 2024 |
As filed with the Securities and Exchange Commission on August 20, 2024 As filed with the Securities and Exchange Commission on August 20, 2024 Registration No. |
|
| August 7, 2024 |
Exhibit 10.9 February 22, 2024 Liz Thompson [email protected] Dear Liz: I am absolutely delighted to offer you the position of EVP, Head of Research & Development with Acadia Pharmaceuticals Inc. (the "Company" or "Acadia"). In your role, you will report directly to me in my role as CEO. The terms of your employment are subject to satisfactory completion of a background investigation, and review |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-50768 ACADIA PHARMACEUTICALS INC. (Exact Name of Registrant a |
|
| August 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2024 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 6, 2024 |
Exhibit 99.1 Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview - Second quarter total net product sales of $242.0 million, up 46% year-over-year SAN DIEGO, CA, August 6, 2024 – Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2024. “In the second quarter of 2024, Acadia delivered $242.0 |
|
| May 29, 2024 |
Exhibit 99.3 Standard Form ACADIA PHARMACEUTICALS INC. RSU AWARD GRANT NOTICE (2024 EQUITY INCENTIVE PLAN) Acadia Pharmaceuticals Inc. (the “Company”) has awarded to you (the “Participant”) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the “RSU Award”). Your RSU Award is subject to all of the terms and conditions as set forth her |
|
| May 29, 2024 |
As filed with the Securities and Exchange Commission on May 29, 2024 As filed with the Securities and Exchange Commission on May 29, 2024 Registration No. |
|
| May 29, 2024 |
As filed with the Securities and Exchange Commission on May 29, 2024 S-8 As filed with the Securities and Exchange Commission on May 29, 2024 Registration No. |
|
| May 29, 2024 |
As filed with the Securities and Exchange Commission on May 29, 2024 As filed with the Securities and Exchange Commission on May 29, 2024 Registration No. |
|
| May 29, 2024 |
Exhibit 99.5 Director Form ACADIA PHARMACEUTICALS INC. RSU AWARD GRANT NOTICE (2024 EQUITY INCENTIVE PLAN) Acadia Pharmaceuticals Inc. (the “Company”) has awarded to you (the “Participant”) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the “RSU Award”). Your RSU Award is subject to all of the terms and conditions as set forth her |
|
| May 29, 2024 |
Exhibit 99.2 Standard Form ACADIA PHARMACEUTICALS INC. STOCK OPTION GRANT NOTICE (2024 EQUITY INCENTIVE PLAN) Acadia Pharmaceuticals Inc. (the “Company”), pursuant to its 2024 Equity Incentive Plan (the “Plan”), has granted to you (“Optionholder”) an option to purchase the number of shares of the Common Stock set forth below (the “Option”). Your Option is subject to all of the terms and conditions |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 29, 2024 |
As filed with the Securities and Exchange Commission on May 29, 2024 As filed with the Securities and Exchange Commission on May 29, 2024 Registration No. |
|
| May 29, 2024 |
As filed with the Securities and Exchange Commission on May 29, 2024 As filed with the Securities and Exchange Commission on May 29, 2024 Registration No. |
|
| May 29, 2024 |
Exhibit 99.1 ACADIA PHARMACEUTICALS INC. 2024 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: April 10, 2024 APPROVED BY THE STOCKHOLDERS: May 29, 2024 1. GENERAL. (a) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan or the Inducement Plan; (i |
|
| May 29, 2024 |
As filed with the Securities and Exchange Commission on May 29, 2024 As filed with the Securities and Exchange Commission on May 29, 2024 Registration No. |
|
| May 29, 2024 |
As filed with the Securities and Exchange Commission on May 29, 2024 As filed with the Securities and Exchange Commission on May 29, 2024 Registration No. |
|
| May 29, 2024 |
As filed with the Securities and Exchange Commission on May 29, 2024 As filed with the Securities and Exchange Commission on May 29, 2024 Registration No. |
|
| May 29, 2024 |
As filed with the Securities and Exchange Commission on May 29, 2024 As filed with the Securities and Exchange Commission on May 29, 2024 Registration No. |
|
| May 29, 2024 |
As filed with the Securities and Exchange Commission on May 29, 2024 As filed with the Securities and Exchange Commission on May 29, 2024 Registration No. |
|
| May 29, 2024 |
Exhibit 107 Calculation of Filing Fees Tables Form S-8 (Form Type) Acadia Pharmaceuticals Inc. |
|
| May 29, 2024 |
Exhibit 99.4 Director Form ACADIA PHARMACEUTICALS INC. STOCK OPTION GRANT NOTICE (2024 EQUITY INCENTIVE PLAN) Acadia Pharmaceuticals Inc. (the “Company”), pursuant to its 2024 Equity Incentive Plan (the “Plan”), has granted to you (“Optionholder”) an option to purchase the number of shares of the Common Stock set forth below (the “Option”). Your Option is subject to all of the terms and conditions |
|
| May 9, 2024 |
Exhibit 10.3 Acadia Pharmaceuticals Inc. Performance Stock Unit Grant Notice (2010 Equity Incentive Plan, as Amended) Acadia Pharmaceuticals Inc. (the “Company”), pursuant to its 2010 Equity Incentive Plan, as amended (the “Plan”), hereby awards to Participant a Performance Stock Unit Award for the number of shares of the Company’s Common Stock (“Performance Stock Units”) set forth below (the “Awa |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-50768 ACADIA PHARMACEUTICALS INC. (Exact Name of Registrant |
|
| May 9, 2024 |
Exhibit 10.2 Exhibit A ACADIA Pharmaceuticals, Inc. Restricted Stock Unit Grant Notice (2010 Equity Incentive Plan, as Amended) ACADIA Pharmaceuticals, Inc. (the “Company”), pursuant to its 2010 Equity Incentive Plan, as amended (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below |
|
| May 9, 2024 |
Exhibit 10.1 ACADIA PHARMACEUTICALS INC. NONSTATUTORY STOCK OPTION GRANT NOTICE (2010 EQUITY INCENTIVE PLAN) ACADIA PHARMACEUTICALS INC. (the “Company”), pursuant to its 2010 Equity Incentive Plan, as amended (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions |
|
| May 8, 2024 |
Exhibit 99.1 Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview - First quarter NUPLAZID® (pimavanserin) net product sales of $129.9 million - First quarter DAYBUE™ (trofinetide) net product sales of $75.9 million SAN DIEGO, CA, May 8, 2024 – Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31 |
|
| May 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2024 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 26, 2024 |
ADIA 2023 PROXY STATEMENT SCHEDULE 14A ACADIA 2024 PROXY STATEMENT Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to § 240. |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 28, 2024 |
Exhibit 10.18 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. First Amendment to Product Agreement between Patheon Pharmaceuticals Inc. and ACADIA Pharmaceuticals Inc. This First Amendment to Product Agreement (the “Amendment”), dated Apri |
|
| February 28, 2024 |
Exhibit 10.5 ACADIA Pharmaceuticals, Inc. Restricted Stock Unit Award Grant Notice 2010 Equity Incentive Plan ACADIA Pharmaceuticals, Inc. (the “Company”) hereby awards to Participant the number of Restricted Stock Units specified and on the terms set forth below (the “Award”). The Award is subject to all of the terms and conditions as set forth in this Restricted Stock Unit Award Grant Notice (th |
|
| February 28, 2024 |
Acadia Pharmaceuticals Inc. Dodd-Frank Clawback Policy. Exhibit 97.1 ACADIA PHARMACEUTICALS INC. DODD-FRANK CLAWBACK POLICY Acadia Pharmaceuticals Inc. (“Company”) has adopted this clawback policy (the “Policy”) as an amendment and restatement of any other clawback policies in effect now at the Company. To the extent this Policy applies to compensation payable to a person covered by this Policy, it shall be the only clawback policy applicable to such c |
|
| February 28, 2024 |
Exhibit 10.36 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Commercial Supply Agreement This Commercial Supply Agreement is entered into as of December 15, 2021 (the Effective Date) between F.I.S. Fabbrica Italiana Sintetici S.p.A., an Ita |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50768 ACADIA PHARMAC |
|
| February 28, 2024 |
Exhibit 10.37 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. PRODUCT AGREEMENT Pursuant to the Master Manufacturing Services Agreement dated August 3, 2015 between Patheon Pharmaceuticals Inc., and Acadia Pharmaceuticals Inc., as amended Ja |
|
| February 28, 2024 |
Exhibit 10.35 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. MASTER COMMERCIAL SUPPLY AGREEMENT THIS COMMERCIAL SUPPLY AGREEMENT (the “Agreement” or this “CSA”) is made and entered into the 16th day of November , 2022 (the “Effective Date”) |
|
| February 28, 2024 |
Exhibit 10.19 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Second Amendment to Product Agreement between Patheon Pharmaceuticals Inc. and ACADIA Pharmaceuticals Inc. This Second Amendment to Product Agreement (the “Amendment”), dated Oc |
|
| February 28, 2024 |
Exhibit 10.13 January 12, 2024 Jennifer Rhodes [email protected] Dear Jennifer: We are delighted to offer you the position of EVP, Chief Legal Officer with Acadia Pharmaceuticals Inc. (the “Company” or “Acadia”). As discussed with you, this offer is contingent subject to your satisfactory completion of a background investigation, including contact with your professional references, and review |
|
| February 28, 2024 |
Exhibit 10.20 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Third Amendment to Product Agreement between Patheon Pharmaceuticals Inc. and ACADIA Pharmaceuticals Inc. This Third Amendment to Product Agreement (this “Amendment”), dated Dec |
|
| February 28, 2024 |
Exhibit 10.38 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. COMMERCIAL SUPPLY AGREEMENT This Commercial Supply Agreement is made as of this 1st day of March, 2023 (the “Effective Date”), by and between ACADIA Pharmaceuticals Inc., a Delawa |
|
| February 28, 2024 |
List of subsidiaries of the Registrant. Exhibit 21.1 List of Subsidiaries NAME OF SUBSIDIARY JURISDICTION OF INCORPORATION ACADIA Pharmaceuticals A/S Denmark ACADIA Pharmaceuticals GmbH Switzerland ACADIA Pharma Limited CerSci Therapeutics Incorporated Amorsa Therapeutics Inc. United Kingdom Delaware Delaware Acadia Pharmaceuticals Holdings Inc. Delaware Levo Therapeutics, Inc. Delaware Pandeia Therapeutics United Kingdom |
|
| February 28, 2024 |
Exhibit 10.17 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Master Manufacturing Services Agreement August 3, 2015 Master Manufacturing Services Agreement Table of Contents ARTICLE 1 1 Structure of Agreement and Interpretation 1 1.1 Mast |
|
| February 27, 2024 |
Exhibit 99.1 Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview - 2023 total net product sales of $726.4 million, reflecting 40% revenue growth. - Fourth quarter DAYBUE™ (trofinetide) net product sales of $87.1 million and full year 2023 net product sales of $177.2 million. - Fourth quarter NUPLAZID® (pimavanserin) net product sales of $143.9 |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 14, 2024 |
ACAD / ACADIA Pharmaceuticals Inc. / RTW INVESTMENTS, LP Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Acadia Pharmaceuticals Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 004225108 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule purs |
|
| February 13, 2024 |
ACAD / ACADIA Pharmaceuticals Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0169-acadiapharmaceuticals.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: ACADIA Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 004225108 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box |
|
| January 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2024 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2023 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-50768 ACADIA PHARMACEUTICALS INC. (Exact Name of Registr |
|
| November 2, 2023 |
Exhibit 99.1 Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview - Company reports record revenues resulting from strong DAYBUE launch and growth in NUPLAZID franchise - 3Q23 DAYBUE™ (trofinetide) net product sales of $66.9 million - 3Q23 NUPLAZID® (pimavanserin) net product sales of $144.8 million SAN DIEGO, CA, November 2, 2023 – Acadia Pharmaceuticals Inc. |
|
| November 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 02, 2023 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Comm |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-50768 ACADIA PHARMACEUTICALS INC. (Exact Name of Registrant a |
|
| August 3, 2023 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Joint Venture and Licence Agreement Neuren Pharmaceuticals Limited ABN 72 111 496 130 Acadia Pharmaceuticals Inc Joint Venture and Licence Agreement Table of Contents Details 1 1 |
|
| August 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 02, 2023 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 2, 2023 |
Exhibit 99.1 Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview - 2Q23 DAYBUE™ (trofinetide) net product sales of $23.2 million - 2Q23 NUPLAZID® (pimavanserin) net product sales of $142.0 million - Expanded licensing agreement for trofinetide includes ex-North American rights SAN DIEGO, CA, August 2, 2023 – Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today a |
|
| July 18, 2023 |
EX-99.1 Exhibit 99.1 Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome — Expanded agreement follows Acadia’s April 2023 U.S. launch of DAYBUE™ (trofinetide) as the first and only drug approved for the treatment of Rett syndrome — Acadia provides DAYBUE launch update and announces second quarter pre |
|
| July 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2023 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 24, 2023 |
Exhibit 99.2 PROCEEDS AGREEMENT AGREEMENT dated as of May 23, 2023 by and between Baker Bros. Advisors LP (the “Management Company”) and Dr. Stephen Biggar (the “Agent”). WHEREAS, the Agent, in his capacity as a director of ACADIA Pharmaceuticals Inc. (the “Company”), received non-transferable options (the “Options”) to purchase 12,500 shares of the Company common stock (the “Stock”) according to |
|
| May 24, 2023 |
ACAD / Acadia Pharmaceuticals Inc / BAKER BROS. ADVISORS LP - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| May 24, 2023 |
Loan Agreement Between Baker Brothers Life Sciences, L.P., 667, L.P. and Baker Bros. Advisors LP Exhibit 99.1 Loan Agreement Between Baker Brothers Life Sciences, L.P., 667, L.P. and Baker Bros. Advisors LP For value received, Baker Bros. Advisors LP (the “Management Company”) promises to pay Baker Brothers Life Sciences, L.P. and 667, L.P., (collectively “The Funds”), the amounts set forth in Schedule A below, payable on the Due Date (as defined below) with interest payable through the Due D |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-50768 ACADIA PHARMACEUTICALS INC. (Exact Name of Registrant |
|
| May 8, 2023 |
Exhibit 99.1 Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older on March 10, 2023 - Announced DAYBUE Availability on April 17, 2023 SAN DIEGO, CA, May 8, 2023 – A |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2023 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 1, 2023 |
ADIA 2023 PROXY STATEMENT SCHEDULE 14A ACADIA 2023 PROXY STATEMENT Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to § 240. |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 28, 2023 |
Exhibit 10.36 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LEASE AND LEASE AGREEMENT Between Boston Properties Limited Partnership The Landlord And ACADIA PHARMACEUTICALS INC. The Tenant For Leased Premises In 502 Carnegie Center Princeto |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50768 ACADIA PHARMAC |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 28, 2023 |
List of subsidiaries of the Registrant. Exhibit 21.1 List of Subsidiaries NAME OF SUBSIDIARY JURISDICTION OF INCORPORATION ACADIA Pharmaceuticals A/S Denmark ACADIA Pharmaceuticals GmbH Switzerland ACADIA Pharma Limited CerSci Therapeutics Incorporated Amorsa Therapeutics Inc. United Kingdom Delaware Delaware Acadia Pharmaceuticals Holdings Inc. Delaware Levo Therapeutics, Inc. Delaware Pandeia Therapeutics United Kingdom |
|
| February 28, 2023 |
Exhibit 99.1 Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12, 2023, for trofinetide for the treatment of Rett syndrome SAN DIEGO, CA, February 27, 2023 – Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), |
|
| February 28, 2023 |
Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson. Exhibit 10.12 December 19, 2022 Doug Williamson [email protected] Dear Doug: We are delighted to offer you the position of Executive Vice President, Research and Development with Acadia Pharmaceuticals Inc. As discussed with you, this offer is contingent subject to your satisfactory completion of a background investigation. The start date for your employment with Acadia will be mutually |
|
| February 9, 2023 |
ACAD / ACADIA Pharmaceuticals Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: ACADIA Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 004225108 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 7, 2023 |
EX-99.2 Exhibit 99.2 ACADIA PHARMACEUTICALS INC. NONSTATUTORY STOCK OPTION GRANT NOTICE (2023 INDUCEMENT PLAN) ACADIA PHARMACEUTICALS INC. (the “Company”), pursuant to its 2023 Inducement Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth he |
|
| February 7, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fees Tables Form S-8 (Form Type) Acadia Pharmaceuticals Inc. |
|
| February 7, 2023 |
As filed with the Securities and Exchange Commission on February 6, 2023 S-8 As filed with the Securities and Exchange Commission on February 6, 2023 Registration No. |
|
| February 7, 2023 |
EX-99.1 Exhibit 99.1 ACADIA PHARMACEUTICALS INC. 2023 INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY 1, 2023 1. GENERAL. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) and the related guidance under Nasdaq IM 5635-1. A person wh |
|
| February 7, 2023 |
EX-99.3 Exhibit 99.3 ACADIA PHARMACEUTICALS, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2023 INDUCEMENT PLAN) ACADIA Pharmaceuticals, Inc. (the “Company”), pursuant to its 2023 Inducement Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). The Award is subject to |
|
| January 17, 2023 |
EX-99.2 3 tm233610d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 PROCEEDS AGREEMENT AGREEMENT dated as of January 12, 2023 by and between Baker Bros. Advisors LP (the “Management Company”) and Dr. Stephen Biggar (the “Agent”). WHEREAS, the Agent, in his capacity as a director of ACADIA Pharmaceuticals Inc. (the “Company”), received non-transferable options (the “Options”) to purchase 15,000 shares of the |
|
| January 17, 2023 |
ACAD / ACADIA Pharmaceuticals Inc. / BAKER BROS. ADVISORS LP - SC 13D/A Activist Investment SC 13D/A 1 tm233610d1sc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 15)* ACADIA Pharmaceuticals Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 004225108 |
|
| January 17, 2023 |
Loan Agreement Between Baker Brothers Life Sciences, L.P., 667, L.P. and Baker Bros. Advisors LP EX-99.1 2 tm233610d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Loan Agreement Between Baker Brothers Life Sciences, L.P., 667, L.P. and Baker Bros. Advisors LP For value received, Baker Bros Advisors LP (the “Management Company”) promises to pay Baker Brothers Life Sciences, L.P. and 667, L.P., (collectively “The Funds”), the amounts set forth in Schedule A below, payable on the Due Date (as defined bel |
|
| November 3, 2022 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. CHANGE ORDER # 1 to MSA Attachment No. 1 [***] This Change Order #1 to MSA Attachment No. 1 (?Change Order?), is effective as of January 3, 2017, and amends certain provisions of t |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-50768 ACADIA PHARMACEUTICALS INC. (Exact Name of Registr |
|
| November 3, 2022 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Master Services Agreement This Agreement is entered into as of December 15, 2016 (the Effective Date) between Siegfried AG Untere Bruehlstrasse 4, 4800 Zofingen, Switzerland (Siegf |
|
| November 3, 2022 |
Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. MSA Attachment No.4 This MSA Attachment No.4 (MSA Attachment No.4) is entered into among Siegfried Evionnaz SA, route du Simplon 1, 1902 Evionnaz, Switzerland (Siegfried Evionnaz) |
|
| November 2, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 02, 2022 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 2, 2022 |
Exhibit 99.1 . Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results - 3Q22 net sales of $130.7 million - Prescription Drug User Fee Act action date set for March 12, 2023 for trofinetide for the treatment of Rett syndrome SAN DIEGO, CA, November 2, 2022 – Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2022. |
|
| October 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commi |
|
| October 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2022 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-50768 ACADIA PHARMACEUTICALS INC. (Exact Name of Registrant a |
|
| August 9, 2022 |
EX-10.1 2 acad-ex101.htm EX-10.1 Exhibit 10.1 ACADIA Pharmaceuticals Inc. 2010 Equity Incentive Plan Adopted by the Board of Directors: March 12, 2010 Approved by the Stockholders: June 11, 2010 Amended by the Board of Directors: April 17, 2013 Approved by the Stockholders: June 7, 2013 Amended by the Board of Directors: April 17, 2015 Approved by the Stockholders: June 15, 2015 Amended by the Boa |
|
| August 9, 2022 |
As filed with the Securities and Exchange Commission on August 8, 2022 As filed with the Securities and Exchange Commission on August 8, 2022 Registration No. |
|
| August 9, 2022 |
2010 Equity Incentive Plan, as amended. Exhibit 99.1 ACADIA PHARMACEUTICALS INC. 2010 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 12, 2010 APPROVED BY THE STOCKHOLDERS: JUNE 11, 2010 AMENDED BY THE BOARD OF DIRECTORS: APRIL 17, 2013 APPROVED BY THE STOCKHOLDERS: JUNE 7, 2013 AMENDED BY THE BOARD OF DIRECTORS: APRIL 17, 2015 APPROVED BY THE STOCKHOLDERS: JUNE 15, 2015 AMENDED BY THE BOARD OF DIRECTORS: APRIL 29, 2016 A |
|
| August 9, 2022 |
Exhibit 107 Calculation of Filing Fees Tables Form S-8 (Form Type) Acadia Pharmaceuticals Inc. |
|
| August 8, 2022 |
Exhibit 99.1 . Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results - 2Q22 net sales of $134.6 million, a 17% increase over 2Q21 - NDA submitted for trofinetide for the treatment of Rett syndrome SAN DIEGO, CA, August 8, 2022 ? Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2022. ?In the second quarter of 2022 |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2022 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commis |
|
| June 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 Acadia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 000-50768 06-1376651 (State or other jurisdiction of incorporation) (Commissio |
|
| May 25, 2022 |
As filed with the Securities and Exchange Commission on May 25, 2022 Table of Contents As filed with the Securities and Exchange Commission on May 25, 2022 Registration No. |
|
| May 25, 2022 |
Calculation of Registration Fee. EX-FILING FEES 4 d327934dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Acadia Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Max |
|
| May 13, 2022 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-50768 ACADIA PHARMACEUTICALS INC. (Exact Name of Registrant |
|
| May 4, 2022 |
Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results - 1Q22 net sales of $115. |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 04, 2022 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 29, 2022 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to ? 240. |
|
| April 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2022 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 1, 2022 |
Exhibit 10.11 April 28, 2020 Mark Schneyer 55 Round Hill Road Scarsdale, NY 10583 Dear Mark: I am delighted to offer you the position of Senior Vice President Business Development and Chief Business Officer with ACADIA Pharmaceuticals Inc. (the ?Company? or ?ACADIA?). The start date for your employment with ACADIA will be mutually agreed to by you and me. The following summarizes the terms of our |
|
| March 1, 2022 |
Exhibit 10.9 Revised Offer Letter June 26, 2018 Brendan Teehan 2690 Kelly Knoll Lane Newbury Park, CA 91320 Dear Brendan: We are delighted to offer to you the position of Vice President, Insights, Analytics, and Commercial Operations with ACADIA Pharmaceuticals Inc. (the ?Company? or ?ACADIA?). The start date for your employment with ACADIA will be Monday, July 16, 2018 or other date mutually agre |
|
| March 1, 2022 |
List of subsidiaries of the Registrant. Exhibit 21.1 List of Subsidiaries NAME OF SUBSIDIARY JURISDICTION OF INCORPORATION ACADIA Pharmaceuticals A/S Denmark ACADIA Pharmaceuticals GmbH Switzerland ACADIA Pharma Limited CerSci Therapeutics Incorporated Amorsa Therapeutics Inc. United Kingdom Delaware Delaware Acadia Pharmaceuticals Holdings Inc. Delaware |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50768 ACADIA PHARMAC |
|
| February 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 28, 2022 |
Exhibit 99.1 Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results - Full year 2021 net sales grew to $484.1 million, a 10% increase over 2020 - Resubmitted sNDA for pimavanserin for the treatment of Alzheimer's disease psychosis - Delivered positive top-line results from the pivotal Phase 3 Lavender trial evaluating trofinetide for the treatment of Rett syndrome SAN D |
|
| February 9, 2022 |
ACAD / ACADIA Pharmaceuticals Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: ACADIA Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 004225108 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| December 21, 2021 |
Exhibit 99.1 Acadia Pharmaceuticals Announces Plan for a Resubmission of its Supplemental New Drug Application to U.S. FDA for NUPLAZID? (pimavanserin) - Acadia plans to resubmit its sNDA in the first quarter of 2022 - Conference call and webcast to be held today at 4:30 p.m. Eastern Time SAN DIEGO, CA, December 20, 2021 ? Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that it plans to |
|
| December 21, 2021 |
Exhibit 99.2 Regulatory Update on sNDA for ? NUPLAZID (pimavanserin) December 20, 2021 Call Agenda Introduction Mark Johnson | Vice President, Investor Relations CEO Opening Remarks Steve Davis | Chief Executive Officer Regulatory Update Serge Stankovic, M.D., M.S.P.H | President CEO Closing Remarks Steve Davis | Chief Executive Officer Also available for Q&A: Mark Schneyer | Chief Financial Offic |
|
| December 21, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2021 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Comm |
|
| December 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2021 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 14, 2021 |
Exhibit 99.1 Acadia Pharmaceuticals Announces Promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer SAN DIEGO?(BUSINESS WIRE)? Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer (CFO), effective immediately. Mr. Schneyer has served as the company?s interim CFO since September 2021, |
|
| December 6, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2021 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 6, 2021 |
Exhibit 99.1 Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome - Trofinetide met co-primary efficacy endpoints demonstrating statistically significant improvement over placebo in the Rett Syndrome Behaviour Questionnaire (RSBQ) (p=0.0175) and the Clinical Global Impression of Improvement (CGI-I) (p=0.0030) - Trofineti |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-50768 ACADIA PHARMACEUTICALS INC. (Exact Name of Registr |
|
| November 8, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 8, 2021 |
EX-99.1 2 acad-ex9916.htm EX-99.1 Exhibit 99.1 Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results - 3Q21 net sales of $131.6 million, a 9% increase over 3Q20 - FDA meeting scheduled to discuss next steps towards a resubmission of the pimavanserin sNDA SAN DIEGO, CA, November 8, 2021 – Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third q |
|
| November 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2021 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 5, 2021 |
Exhibit 99.1 November 1, 2021 Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial SAN DIEGO?(BUSINESS WIRE)? Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the promotion of Brendan Teehan to Executive Vice President, Chief Operating Officer, Head of Commercial, effective immediately. Mr. Teehan, previously Senior Vice Pr |
|
| September 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2021 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-50768 ACADIA PHARMACEUTICALS INC. (Exact Name of Registrant a |
|
| August 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 4, 2021 |
EX-99.1 2 acad-ex9916.htm EX-99.1 Exhibit 99.1 Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results - 2Q21 net sales of $115.2 million, a 5% increase over 2Q20 - Fiscal year 2021 revenue guidance reduced to $480 to $515 million - Type A meeting held with FDA regarding DRP; Acadia will continue discussion with FDA in another meeting later this year SAN DIEGO, CA, August 4, 2021 – Ac |
|
| June 24, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2021 Acadia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 000-50768 06-1376651 (State or other jurisdiction of incorporation or organiz |
|
| May 12, 2021 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 6, 2021 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT ACADIA PHARMACEUTICALS, INC. |
|
| May 6, 2021 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT ACADIA PHARMACEUTICALS, INC. |
|
| May 6, 2021 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT ACADIA PHARMACEUTICALS, INC. |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-50768 ACADIA PHARMACEUTICALS INC. (Exact Name of Registrant |
|
| May 6, 2021 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT ACADIA PHARMACEUTICALS, INC. |
|
| May 5, 2021 |
EX-99.1 2 acad-ex9916.htm EX-99.1 Exhibit 99.1 Acadia Pharmaceuticals Reports First Quarter 2021 Financial Results - 1Q21 net sales of $106.6 million, an 18% increase over 1Q20 - Reiterating FY21 net sales guidance of $510 to $550 million SAN DIEGO, CA, May 5, 2021 – Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2021. “NUPLA |
|
| May 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 30, 2021 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to ? 240. |
|
| April 5, 2021 |
Exhibit 99.2 Regulatory Update on DRP sNDA April 5, 2021Exhibit 99.2 Regulatory Update on DRP sNDA April 5, 2021 Agenda Introduction Mark Johnson | Vice President, Investor Relations CEO Opening Remarks Steve Davis | Chief Executive Officer Discussion Serge Stankovic, M.D., M.S.P.H | President CEO Closing Remarks Steve Davis | Chief Executive Officer Steve Davis | Chief Executive Officer Q&A Serge |
|
| April 5, 2021 |
Exhibit 99.1 Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis - Conference call and webcast to be held today at 8:00 a.m. Eastern Time SAN DIEGO April 5, 2021 ? Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the C |
|
| April 5, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2021 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 8, 2021 |
EX-99.1 Exhibit 99.1 Acadia Pharmaceuticals Provides Regulatory Update on Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis - Conference call and webcast to be held today at 5:00 p.m. Eastern Time SAN DIEGO March 8, 2021 – Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company receive |
|
| March 8, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2021 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 25, 2021 |
Employment Offer Letter, dated April 2, 2018, between the Registrant and Elena Ridloff. Exhibit 10.11 April 2, 2018 Elena Ridloff 3 Grist Mill Lane Westport, CT06880 Via Email Dear Elena: We are delighted to offer to you the position of Sr. Vice President, Investor Relations with ACADIA Pharmaceuticals Inc. (the ??Company?). You will report to me and will be added to our Executive Management Committee. This position will be based remotely. Subject to the completion of a background in |
|
| February 25, 2021 |
List of subsidiaries of the Registrant. Exhibit 21.1 List of Subsidiaries NAME OF SUBSIDIARY JURISDICTION OF INCORPORATION ACADIA Pharmaceuticals A/S Denmark ACADIA Pharmaceuticals GmbH Switzerland ACADIA Pharma Limited CerSci Therapeutics Incorporated United Kingdom Delaware |
|
| February 25, 2021 |
Exhibit 3.2 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ACADIA PHARMACEUTICALS INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware ACADIA Pharmaceuticals Inc., a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the ?Corporation?), does hereby certify that: 1. The Amended and Res |
|
| February 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50768 ACADIA PHARMAC |
|
| February 24, 2021 |
Exhibit 99.1 Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results - Full year 2020 net sales grew to $441.8 million, a 30% increase over 2019 - Upcoming PDUFA action date of April 3, 2021 for supplemental New Drug Application for pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis SAN DIEGO, CA, February 24, 2021 ? |
|
| February 24, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2021 Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: ACADIA Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 004225108 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| January 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2021 ACADIA Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 4, 2020 |
Exhibit 99.1 Acadia Pharmaceuticals Reports Third Quarter 2020 Financial Results - 3Q20 Net Sales of $120.6 Million, a 27% Increase Over 3Q19 SAN DIEGO, CA, November 4, 2020 – Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today annou |
|
| November 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2020 ACADIA Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-50768 ACADIA PHARMACEUTICALS INC. (Exact Name of Registr |
|
| November 4, 2020 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. MSA Attachment No. 7 This MSA Attachment (MSA Attachment) is entered into between Siegfried AG, Untere Bruehlstrasse 4, 4800 Zofingen, Switzerland (Siegfried) and ACADIA Pharmaceuticals Gm |
|
| October 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2020 ACADIA Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Com |
|
| August 25, 2020 |
EX-99.1 Exhibit 99.1 ACADIA Pharmaceuticals Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio - First-in-class, non-opioid, mechanism interrupts pain pathways - Phase 2 initiation planned for the first half of 2021 SAN DIEGO, CA, and FORT WORTH, TX - Aug 25, 2020 – ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the acquisition of CerSci Therapeutics, a clinical-stage b |
|
| August 25, 2020 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2020 ACADIA Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 25, 2020 |
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on August 25, 2020 Registration No. |
|
| August 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-50768 ACADIA PHARMACEUTICALS INC. (Exact Name of Registrant a |
|
| August 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2020 ACADIA Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 6, 2020 |
S-8 As filed with the Securities and Exchange Commission on August 6, 2020 Registration No. |
|
| August 5, 2020 |
Exhibit 99.1 ACADIA Pharmaceuticals Reports Second Quarter 2020 Financial Results - 2Q20 Net Sales of $110.1 Million, a 32% Increase Over 2Q19 - FDA filed the supplemental NDA for pimavanserin for the treatment of dementia-related psychosis with a PDUFA action date set for April 3, 2021 - Initiated ADVANCE-2, a Phase 3 study evaluating pimavanserin for the treatment of the negative symptoms of sch |
|
| August 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2020 ACADIA Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| July 20, 2020 |
EX-99.2 EXHIBIT 99.2 ACADIA Pharmaceuticals Announces Top-line Results from the Phase 3 CLARITY Study Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder - The study did not achieve statistical significance on the primary endpoint - Conference call and webcast to be held today at 4:30 p.m. Eastern Time SAN DIEGO, CA, July 20, 2020 – ACADIA Pharmaceuticals Inc. (Nasdaq |
|
| July 20, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2020 ACADIA Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 000-50768 06-1376651 (State or other jurisdiction of incorporation or organiz |
|
| July 20, 2020 |
EX-99.1 EXHIBIT 99.1 ACADIA Announces U.S. FDA Accepted for Filing the Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis - If approved, NUPLAZID would be the first and only treatment indicated for dementia-related psychosis - Prescription Drug User Fee Act (PDUFA) date set for April 3, 2021 - |
|
| June 29, 2020 |
ACADIA PHARMACEUTICALS INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY EX-99.2 Exhibit 99.2 ACADIA PHARMACEUTICALS INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) of ACADIA Pharmaceuticals Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, a “Non-Employee Director”) will, automatically and without further action by the Board or the Compensation Com |
|
| June 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2020 ACADIA Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 000-50768 06-1376651 (State or other jurisdiction of incorporation or organiz |
|
| June 29, 2020 |
EX-99.1 Exhibit 99.1 ACADIA PHARMACEUTICALS INC. 2004 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS ON FEBRUARY 25, 2004 APPROVED BY STOCKHOLDERS ON MAY 5, 2004 AMENDED BY THE BOARD OF DIRECTORS ON APRIL 29, 2016 APPROVED BY STOCKHOLDERS ON JUNE 10, 2016 AMENDED BY THE BOARD OF DIRECTORS: APRIL 27, 2019 APPROVED BY THE STOCKHOLDERS: JUNE 26, 2019 AMENDED BY THE BOARD OF DIRECTORS: |
|
| May 8, 2020 |
EX-10.2 3 acad-ex102303.htm EX-10.2 Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. SECOND AMENDMENT TO OFFICE LEASE This SECOND AMENDMENT TO OFFICE LEASE ("Second Amendment") is made and entered into as of March 12, 2020, by and betw |
|
| May 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-50768 ACADIA PHARMACEUTICALS INC. (Exact Name of Registrant |
|
| May 8, 2020 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. FIRST AMENDMENT TO OFFICE LEASE This FIRST AMENDMENT TO OFFICE LEASE ("First Amendment") is made and entered into as of December 23, 2019, by and between KILROY REALTY, L.P., a Delaware |
|
| May 7, 2020 |
Exhibit 99.1 ACADIA Pharmaceuticals Reports First Quarter 2020 Financial Results - 1Q20 Net Sales of $90.1 Million, a 43% Increase Over 1Q19 - On-track to submit supplemental NDA for pimavanserin for the treatment of dementia-related psychosis (DRP) this summer - Announced worldwide license agreement and collaboration with Vanderbilt University for new central nervous system (CNS) therapeutic prog |
|
| May 7, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 ACADIA Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 29, 2020 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to § 240. |
|
| February 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50768 ACADIA PHARMAC |
|
| February 27, 2020 |
Exhibit 4.3 DESCRIPTION OF COMMON STOCK General The following description summarizes the most important terms of our common stock. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description of the matters set forth in this “Description of Common Stock,” you should refer to our amended and restated certificate of incorporation, as |
|
| February 27, 2020 |
List of subsidiaries of the Registrant. Exhibit 21.1 List of Subsidiaries NAME OF SUBSIDIARY JURISDICTION OF INCORPORATION ACADIA Pharmaceuticals A/S Denmark ACADIA Pharmaceuticals GmbH Switzerland ACADIA Pharma Limited United Kingdom |
|
| February 27, 2020 |
ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results - Full Year 2019 Net Sales Grew to $339. |
|
| February 27, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2020 ACADIA Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 12, 2020 |
ACAD / ACADIA Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: ACADIA Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 004225108 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| January 13, 2020 |
EX-99.1 Steve Davis, CEO 38th Annual J.P. Morgan Healthcare Conference January 14, 2020 Exhibit 99.1 Forward-Looking Statement This presentation contains forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future r |
|
| January 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2020 ACADIA Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 000-50768 06-1376651 (State or other jurisdiction of incorporation or orga |
|
| November 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2019 ACADIA Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 000-50768 06-1376651 (State or other jurisdiction of incorporation or orga |
|
| October 31, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-50768 ACADIA PHARMACEUTICALS INC. (Exact Name of Registr |
|
| October 30, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2019 ACADIA Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commi |
|
| October 30, 2019 |
Exhibit 99.1 ACADIA Pharmaceuticals Reports Third Quarter 2019 Financial Results - 3Q19 Net Sales Grew to $94.6 Million, a 62% Increase Over 3Q18 - 2019 Net Sales Guidance Increased to $330 to $340 Million - Initiated Phase 3 LAVENDER Study of Trofinetide in Rett Syndrome, a Rare Neurodevelopmental Congenital CNS Disorder SAN DIEGO, CA, October 30, 2019 – ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) |
|
| September 20, 2019 |
ACAD / ACADIA Pharmaceuticals, Inc. / Baker Brothers Advisors LP - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| September 18, 2019 |
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock EX-99.1 EXHIBIT 99.1 ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock SAN DIEGO, CA, September 17, 2019 – ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that it intends to offer and sell, |
|
| September 18, 2019 |
ACADIA Pharmaceuticals Prices Public Offering of Common Stock EX-99.2 EXHIBIT 99.2 ACADIA Pharmaceuticals Prices Public Offering of Common Stock SAN DIEGO, CA, September 17, 2019 – ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering |
|
| September 18, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2019 ACADIA Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 000-50768 06-1376651 (State or other jurisdiction of incorporation or or |
|
| September 18, 2019 |
Underwriting Agreement, dated September 17, 2019 EX-1.1 EXHIBIT 1.1 Execution Version 6,250,000 Shares ACADIA PHARMACEUTICALS INC. UNDERWRITING AGREEMENT September 17, 2019 BofA Securities, Inc. J.P. Morgan Securities LLC as Representatives of the several Underwriters c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Ladies and Gentlemen: Introductory. AC |
|
| September 18, 2019 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-228546 CALCULATION OF REGISTRATION FEE TITLE OF EACH CLASS OF SECURITIES TO BE REGISTERED AMOUNT TO BE REGISTERED(1) PROPOSED MAXIMUM OFFERING PRICE PER SHARE PROPOSED MAXIMUM AGGREGATE OFFERING PRICE AMOUNT OF REGISTRATION FEE(2) Common Stock, $0.0001 par value per share 7,187,500 $40.00 $287,500,000 $34,845.00 (1) Incl |
|
| September 17, 2019 |
Subject to Completion, dated September 17, 2019 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-228546 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state or other jurisdiction where the offe |
|
| September 9, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2019 ACADIA Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 000-50768 06-1376651 (State or other jurisdiction of incorporation or org |
|
| September 9, 2019 |
EX-99.1 Exhibit 99.1 ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis - Pimavanserin achieved robust statistical superiority over placebo in time to relapse of dementia-related psychosis at planned interim efficacy analysis - Pimavanserin has the potential to be |
